Ginkgo

Ginkgo Bioworks Announces Participation in the 44th Annual TD Cowen Health Care Conference

Retrieved on: 
Tuesday, February 27, 2024
DNA, Ginkgo, Entrepreneurship, Conference, Online shopping

BOSTON, Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to participate in Cowen's 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 2:10 p.m.

Key Points: 
  • BOSTON, Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to participate in Cowen's 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 2:10 p.m.
  • ET.
  • The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
  • To ask a question ahead of the presentation, please submit them to @ Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected] .

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2023 Results Presentation

Retrieved on: 
Thursday, February 22, 2024
DNA, Q&A, Ginkgo, Online shopping

BOSTON, Feb. 22, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, beginning at 5:30 p.m. ET.

Key Points: 
  • Presentation and Q&A session scheduled for post-market on Thursday, February 29, 2024
    BOSTON, Feb. 22, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, beginning at 5:30 p.m.
  • ET.
  • The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
  • To ask a question ahead of the presentation, please submit them to @ Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected] .

Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

Retrieved on: 
Thursday, February 15, 2024
DNA, Saponin, GMD, Toxicity, Enzyme, Ginkgo Bioworks, Medicine, SVP, Partnership, Animal, Vaccine, ADC, Refrigeration, Vaccination, Shingles, Malaria, COVID-19, Respiratory syncytial virus, Chemical substance, Saccharomyces cerevisiae, CBD, DTRA, Protein, MCDC, QS-21, Plague, Ginkgo

Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.

Key Points: 
  • Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.
  • Currently, only a handful of adjuvants are available for human use in licensed vaccines.
  • Ginkgo will develop a first-generation Adjuvant Development Candidate (ADC) production method, using a heterologous production strain such as brewers' yeast, Saccharomyces cerevisiae.
  • Development of a first-generation ADC production method could facilitate further development of a sustainable mass-production manufacturing process for these complex adjuvants.

Bioluminescent Plants Are Now Even Brighter: Light Bio to Begin Selling Firefly Petunias to Consumers with USDA Approval

Retrieved on: 
Thursday, February 1, 2024
Partnership, Nature, Food security, USDA, Plant, Science, Research, DNA, Genetics, Petunia, Gene, USD, Flower, Synthetic biology, Ginkgo Bioworks, Firefly, Ginkgo, Garden, Luminescence, Phosphorus

The new research builds on an earlier discovery for creating continuously glowing plants by inserting DNA obtained from the mushrooms.

Key Points: 
  • The new research builds on an earlier discovery for creating continuously glowing plants by inserting DNA obtained from the mushrooms.
  • Light Bio is excited to begin taking orders today for its category-defining Firefly Petunias, available at www.light.bio , today.
  • Light Bio chose the petunia as its first product because it is one of the most popular ornamental plants in the world.
  • In addition to the pure joy these plants bring, the underlying science also helps to elucidate the molecular physiology of plants.

Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world

Retrieved on: 
Monday, January 15, 2024
Research, Health, SAN, DNA, Software, Investment, Pandemic, Biosecurity, Concentric objects, Ginkgo, Marketing, Ginkgo Bioworks, Vaccine

BOSTON and SAN DIEGO, Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.

Key Points: 
  • Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets.
  • Illumina offers a range of leading next-generation sequencing instruments, consumables, and software to understand pathogens in ways not previously possible.
  • Together, Concentric and Illumina are working to help ensure that nations worldwide are equipped and empowered, locally and sustainably.
  • "Illumina is proud to partner with Concentric by Ginkgo to empower countries to protect the health of their citizens from infectious threats."

Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 10, 2024
Cloud, DNA, Partnership, Novo Nordisk, Biogen, AI, Pfizer, Conference, Cell engineering, Pressure, Ginkgo, Boehringer Ingelheim, Google Cloud, Merck, Growth

BOSTON, Jan. 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced preliminary performance updates for the year ended December 31, 2023. Among the results, Ginkgo highlighted that it expects to meet its previously disclosed new program and revenue guidance ranges in 2023 based on its preliminary unaudited estimates. A business review, including a discussion of Ginkgo's platform services for large scale data generation and AI to enable biopharma R&D, will be featured in a presentation today at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • ET)
    BOSTON, Jan. 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced preliminary performance updates for the year ended December 31, 2023.
  • Among the results, Ginkgo highlighted that it expects to meet its previously disclosed new program and revenue guidance ranges in 2023 based on its preliminary unaudited estimates.
  • A business review, including a discussion of Ginkgo's platform services for large scale data generation and AI to enable biopharma R&D, will be featured in a presentation today at the 42nd Annual J.P. Morgan Healthcare Conference.
  • J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
    As previously announced, co-founder and CEO Jason Kelly is scheduled to participate in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT (12:45 p.m.

Ginkgo Bioworks Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
Ginkgo, Entrepreneurship, Conference, DNA, Online shopping

BOSTON, Jan. 3, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT (12:45 p.m.

Key Points: 
  • BOSTON, Jan. 3, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT (12:45 p.m.
  • ET).
  • The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
  • To ask a question ahead of the presentation, please submit them to @ Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected] .

Singapore's Largest Brick-and-Mortar Nutrition Brand LAC Launches Nutrition for Life Campaign, Advocates Holistic Wellness with Minimal Effort

Retrieved on: 
Tuesday, November 21, 2023
Liver, Extrapyramidal system, Dermatitis, Work, Census of agriculture, Risk, Immune system, Woman, Ginkgo, Health, Hawthorn, Life, Nutrient, Lotus, Blood, Brain, SUPER, Medicine, DHA, Digestion, COVID, Thiamine, EPA, Radical, Infection, Oxidative stress, Liver disease, Mother, Forgetting, Memory, Immunity, Fatigue, Skin, Vitamin B3, Dietary supplement

This is the first LAC-branded event since the health and wellness brand opened 54 physical stores in Singapore, further increasing its footprint in the region.

Key Points: 
  • This is the first LAC-branded event since the health and wellness brand opened 54 physical stores in Singapore, further increasing its footprint in the region.
  • "The Nutrition for Life campaign embodies LAC's commitment to inspire Singaporeans to lead healthier and more fulfilling lifestyles.
  • Our range of proprietary blends is a step towards helping people seamlessly incorporate supplements into their daily lives.
  • LAC MASQUELIER's(R) French Pine Bark Extract: SUPER ANTIOXIDANT, Perfect for Immunity Boosting
    Start the day with Masquelier's French Pine Bark.

GreenLab Selects Ginkgo Enzyme Services to Develop Novel Enzyme That Breaks Down 'Forever Chemicals'

Retrieved on: 
Tuesday, December 19, 2023
SAFF, Partnership, Risk, Immune system, Research, Ginkgo, Health, DNA, Cancer, Plant, Food, Enzyme, PFAS, Nature, Soil, Environment, Fine chemical

GreenLab is developing a product with the purpose of degrading PFAS and will leverage Ginkgo Enzyme Services to discover a novel enzyme of critical importance for use in this application.

Key Points: 
  • GreenLab is developing a product with the purpose of degrading PFAS and will leverage Ginkgo Enzyme Services to discover a novel enzyme of critical importance for use in this application.
  • Ginkgo Enzyme Services provides companies with end-to-end enzyme discovery and optimization R&D services.
  • GreenLab aims to tackle this difficult enzymological problem by leveraging Ginkgo Enzyme Services to discover and develop a novel enzyme for use in their PFAS degradation application.
  • To learn more about Ginkgo Enzyme Services and how you can access Ginkgo's success-based pricing, visit ginkgobioworks.com/enzyme-services/ .

U.S. Department of Energy Awards Team Led by Ginkgo Bioworks Funding to Develop Algal Crop Protection Solutions

Retrieved on: 
Tuesday, December 19, 2023
Colorado School of Mines, ALE, Pacific Northwest National Laboratory, Sunlight, Government, Metagenomics, Research, Ginkgo Bioworks, Ginkgo, DNA, Cosmetics, Aquaculture, AMPS, Plant, Biofuel, Animal, Pond, DOE, Dicarboxylic acid, AMP, Carbon, Bacteria, CO2, Agriculture

The scope of the project will be to develop a new approach to algal crop protection, inspired by integrated pest management strategies used for terrestrial crops.

Key Points: 
  • The scope of the project will be to develop a new approach to algal crop protection, inspired by integrated pest management strategies used for terrestrial crops.
  • The awarded project is part of DOE's investment in the development of clean energy solutions that reduce greenhouse gas emissions .
  • "We built our platform to help partners in sustainability like the DOE to enable novel and improved energy solutions.
  • If successful, this BETO investment has the potential to unlock a new suite of algal crop protection strategies to enhance productivity in outdoor environments.